Prevpac

Cat-Scratch Disease, Sinusitis, Whooping Cough + 14 more

Treatment

21 FDA approvals

20 Active Studies for Prevpac

What is Prevpac

Clarithromycin

The Generic name of this drug

Treatment Summary

Lansoprazole, sold under the brand name Prevacid, is a medication that reduces the production of stomach acid. It works by targeting the gastric H,K-ATPase pumps and is commonly used to treat ulcerative diseases, gastroesophageal reflux disease (GERD), and other conditions caused by too much stomach acid.

Biaxin

is the brand name

image of different drug pills on a surface

Prevpac Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Biaxin

Clarithromycin

1991

187

Approved as Treatment by the FDA

Clarithromycin, also known as Biaxin, is approved by the FDA for 21 uses which include Acute maxillary sinusitis and Bacterial Infections .

Acute maxillary sinusitis

Bacterial Infections

Otitis Media (OM)

Mycobacterial Infections

uncomplicated skin and subcutaneous tissue bacterial infections

prophylaxis of Mycobacterial infection

Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB)

Duodenal ulcer caused by helicobacter pylori

Used to treat Duodenal ulcer caused by helicobacter pylori in combination with Amoxicillin

Tonsillitis streptococcal

Streptococcal Pharyngitis

Bronchitis, Chronic

Urinary Tract Infection (UTI)

HIV

Otitis

Duodenal Ulcer

Used to treat Duodenal ulcer caused by helicobacter pylori in combination with Amoxicillin

Mycobacterium Infections

Sinusitis

Community Acquired Pneumonia (CAP)

Bacterial Infections

Tuberculosis

Tonsillitis

Effectiveness

How Prevpac Affects Patients

Lansoprazole works by blocking the enzyme that helps produce stomach acid. It is effective throughout the day and night, and is used to treat ulcers, reduce pain related to ulcers, and relieve heartburn symptoms. It can also be used to lower the amount of acid produced in people with conditions like Zollinger-Ellison Syndrome.

How Prevpac works in the body

Lansoprazole is a type of drug called a proton pump inhibitor (PPI). It needs to be activated in an acidic environment. Once activated, it binds to two proteins in the stomach called Cys813 and Cys321, which helps reduce the amount of acid in the stomach. This binding is strong and long-lasting, giving it a long-term effect on reducing acid levels.

When to interrupt dosage

The prescribed dosage of Prevpac is contingent upon the determined condition, such as A History of Gastric or Duodenal Ulcers, Stomach Ulcer and Erosive Esophagitis. The dosage quantity deviates according to the delivery technique described in the table below.

Condition

Dosage

Administration

Mycobacterium Infections

, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg

, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral

Bacterial Infections

, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg

, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral

Tuberculosis

, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg

, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral

Bacterial Endocarditis

, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg

, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral

Duodenal Ulcer

, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg

, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral

HIV

, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg

, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral

Bronchitis, Chronic

, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg

, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral

Bacterial Endocarditis

, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg

, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral

Community Acquired Pneumonia (CAP)

, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg

, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral

Streptococcal Pharyngitis

, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg

, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral

Cat-Scratch Disease

, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg

, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral

Sinusitis

, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg

, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral

Whooping Cough

, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg

, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral

Lyme Disease

, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg

, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral

Urinary Tract Infection (UTI)

, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg

, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral

Tonsillitis

, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg

, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral

Otitis

, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg

, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral

Warnings

Prevpac Contraindications

Condition

Risk Level

Notes

Liver Dysfunction

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Jaundice, Obstructive

Do Not Combine

There are 20 known major drug interactions with Prevpac.

Common Prevpac Drug Interactions

Drug Name

Risk Level

Description

(R)-warfarin

Major

The metabolism of (R)-warfarin can be decreased when combined with Clarithromycin.

(S)-Warfarin

Major

The metabolism of (S)-Warfarin can be decreased when combined with Clarithromycin.

1,2-Benzodiazepine

Major

The metabolism of 1,2-Benzodiazepine can be decreased when combined with Clarithromycin.

3,5-diiodothyropropionic acid

Major

The metabolism of 3,5-diiodothyropropionic acid can be decreased when combined with Clarithromycin.

5-androstenedione

Major

The metabolism of 5-androstenedione can be decreased when combined with Clarithromycin.

Prevpac Toxicity & Overdose Risk

Lansoprazole is usually well-tolerated with few side effects, such as abdominal pain, constipation, diarrhea, and nausea. Very rarely, it can cause a serious skin reaction known as toxic epidermal necrolysis. Taking 600 mg of lansoprazole does not appear to cause any adverse effects or symptoms of overdose. Lansoprazole is classified as Pregnancy Category B in the US, meaning it is likely safe to use during pregnancy. However, there is not enough research available to know if lansoprazole is safe to use while breastfeeding.

image of a doctor in a lab doing drug, clinical research

Prevpac Novel Uses: Which Conditions Have a Clinical Trial Featuring Prevpac?

Four active clinical trials are underway to assess the utility of Prevpac in ameliorating Stomach Ulcers, NSAID-induced Gastric Ulcers and a History of Gastric or Duodenal Ulcers.

Condition

Clinical Trials

Trial Phases

Mycobacterium Infections

0 Actively Recruiting

Whooping Cough

0 Actively Recruiting

HIV

155 Actively Recruiting

Phase 2, Phase 1, Phase 3, Not Applicable, Phase 4, Early Phase 1

Urinary Tract Infection (UTI)

6 Actively Recruiting

Phase 1, Phase 3, Phase 4, Phase 2

Streptococcal Pharyngitis

0 Actively Recruiting

Tonsillitis

0 Actively Recruiting

Community Acquired Pneumonia (CAP)

5 Actively Recruiting

Not Applicable, Phase 1, Phase 3

Otitis

0 Actively Recruiting

Cat-Scratch Disease

0 Actively Recruiting

Sinusitis

0 Actively Recruiting

Bronchitis, Chronic

0 Actively Recruiting

Bacterial Infections

0 Actively Recruiting

Bacterial Endocarditis

1 Actively Recruiting

Not Applicable

Duodenal Ulcer

0 Actively Recruiting

Bacterial Endocarditis

0 Actively Recruiting

Tuberculosis

0 Actively Recruiting

Lyme Disease

3 Actively Recruiting

Phase 1, Phase 2, Phase 3, Not Applicable

Prevpac Reviews: What are patients saying about Prevpac?

5

Patient Review

6/12/2013

Prevpac for Ulcer of Duodenum caused by Bacteria Helicobacter Pylori

I've been on this medication for six days now and have had zero negative side effects other than an increased appetite. This product has really improved my life.

4.3

Patient Review

12/8/2013

Prevpac for Inflammation of the Stomach Lining caused by H. Pylori

This treatment is very effective, but can be quite expensive. My doctor suggested that I buy the three medicines separately, which ended up being much cheaper in the long run.

3.3

Patient Review

2/20/2014

Prevpac for Inflammation of the Stomach Lining caused by H. Pylori

While the Prepac is quite expensive, it only cost me $120 out of pocket. I did experience some side effects like a bad taste in my mouth and headaches, but nothing too severe.

2.7

Patient Review

4/3/2015

Prevpac for Ulcer of Duodenum caused by Bacteria Helicobacter Pylori

I felt nauseated for the first two days after starting this medication, but that went away. However, now I have diarrhea every time I eat while on this med. Additionally, my heart rate is high at night and I've been feeling more anxious. Not sure if the benefits outweigh the costs here.

2.3

Patient Review

5/29/2013

Prevpac for Inflammation of the Stomach Lining caused by H. Pylori

I developed a painful burning sensation on my tongue over the course of five days.

1.7

Patient Review

7/26/2014

Prevpac for Inflammation of the Stomach Lining caused by H. Pylori

I'm on day two of the treatment and, like other reviewers have said, the metallic taste in my mouth is nauseating. I feel tired and it's hard to sleep at night. I don't understand the side effects.I have taken 4 500mg of amoxicillin prior to going to the dentist and have taken clarithromycin for an infection after a root canal, with no problems. Will start eating pribiotic yogart to see if it stems nausia.I hope this is worth it.

1

Patient Review

5/4/2016

Prevpac for Inflammation of the Stomach Lining caused by H. Pylori

I would approach this treatment with caution. I had some really unpleasant side effects that made me feel terrible. If you decide to go ahead with it, be prepared for the possibility of feeling very sick.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about prevpac

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What does Prevpac cost?

"The average cost for a 112-day supply of Prevpac oral kit (500 mg-500 mg-30 mg) is around $1,018, depending on the pharmacy you visit. Prices given are for cash paying customers only and may not be valid with insurance plans."

Answered by AI

What drugs are in a Prevpac?

"The PREVPAC pack contains enough medicine for 30 days. It is made up of two PREVACID 30-mg capsules, four amoxicillin 500-mg capsules, USP, and two clarithromycin 500-mg tablets, USP."

Answered by AI

Is Prevpac an antibiotic?

"The Prevpac medication is a combination of a proton pump inhibitor, a penicillin antibiotic, and a macrolide antibiotic. It is used to prevent stomach ulcers that are caused by infection with Helicobacter pylori bacteria."

Answered by AI

What is Prevpac used to treat?

"This product contains 2 medicines: clarithromycin and amoxicillin.

This product is used to treat stomach/intestinal ulcers caused by the bacteria H. pylori and to prevent the ulcers from returning. Treating an ulcer reduces the risk of serious damage to the lining of the stomach/intestines (such as bleeding, tearing, blockage). This product contains 2 medicines: clarithromycin and amoxicillin. Clarithromycin is in a class of drugs called macrolide antibiotics. Amoxicillin is in a class of drugs called penicillin-like antibiotics."

Answered by AI

Clinical Trials for Prevpac

Image of New Jersey Community Research Initiative in Newark, United States.

AI-DBT for Suicide Prevention in HIV/AIDS

18+
All Sexes
Newark, NJ

One in four older persons living with HIV/AIDS (PLWHA) report at least one suicide attempt in their lifetime, and the risk for death by suicide is 100 times higher in PLWHA than in the general population. Currently, there are no behavioral interventions that specifically address suicide prevention for older PLWHA, despite their unique biopsychosocial and structural risk factors. Through this work, investigators will adapt Dialectical Behavior Therapy, an evidence-based intervention for suicide prevention, for patients with PLWHA to be delivered by an AI-powered conversational Agent developed by our industry partner, Empower Health. Investigators will then pilot test the feasibility, usability, acceptability and preliminary efficacy to improve self-efficacy to manage negative emotions in n=50 older adults living with HIV/AIDS.

Recruiting
Has No Placebo

New Jersey Community Research Initiative (+1 Sites)

Elissa Kozlov, PhD

Image of George Washington University Emergency Department in Washington D.C., United States.

Decision Support Tool for HIV Prevention

18+
All Sexes
Washington D.C., United States

This project will explore the development of a personalized decision support tool to assist with pre-exposure prophylaxis (PrEP) initiation and persistence among patients identified in the emergency department (ED) and urgent care settings as PrEP eligible. First, the investigators will use a sequence of validated implementation science methodologies to develop and validate a decision support tool designed to optimize PrEP persistence by strengthening self-efficacy by addressing the multifaceted medical and social needs of the individual patient. The investigators will then test the preliminary effectiveness of this tool through a pilot stepped wedge implementation trial in two EDs and an urgent care in Baltimore, MD and Washington, DC among 120 PrEP eligible patients to determine PrEP initiation, linkage to care, persistence, and adherence rates.

Phase 1
Waitlist Available

George Washington University Emergency Department (+1 Sites)

Image of The University of Alabama at Birmingham in Birmingham, United States.

Behavioral vs Mindfulness Treatments for Insomnia in HIV

50 - 99
All Sexes
Birmingham, AL

The goal of this clinical trial is to examine the effects of a telephone-delivered Brief Behavioral Treatment Insomnia (BBTI) versus a Brief Mindfulness Treatment (BMT) on cognitive and sleep outcomes in older adults with HIV. The main questions it aims to answer are: What are the effects of BBTI vs BMT on self-reported and observed sleep outcomes in older adults with HIV and insomnia up to 1-year post-intervention? What are the effects of BBTI vs BMT on self-reported and observed cognitive comes in older adults with HIV and insomnia up to 1-year post-intervention? What is the association between Alzheimer's Disease biomarkers and sleep and cognitive outcomes in older adults with HIV receiving BBTI vs BMT? Participants will: * Complete 4 weeks of telephone-delivered BBTI or BMT * Attend baseline, post-intervention, and 1-year post in-person visits for sleep and cognitive assessments * Have blood collected at all three time points

Waitlist Available
Has No Placebo

The University of Alabama at Birmingham (+1 Sites)

Dr. Shameka L Cody, PhD, AGNP-C, PMHNP-BC, FAAN

Image of University of Alabama at Birmingham in Birmingham, United States.

Olfactory Training for HIV

18+
All Sexes
Birmingham, AL

The goal of this study is to examine two types of olfactory interventions (olfactory training vs overnight odor diffuser) in adults with HIV. The two research questions are: 1. Determine if participants find the intervention acceptable and assess feasibility of the study. 2. Determine if the intervention improves olfactory function and cognitive function. Participants will come to our office and be administered the baseline battery of questions including olfactory and cognitive performance tests. Then they will be randomized and sent home with one of the two interventions (below) in which they will engage in it for 8 weeks, after which they come back to our office for the posttest battery of questions including olfactory and cognitive performance test. 1. Olfactory Training at Home -- 4 scents in which they will smell twice a day for 8 weeks. 2. Overnight Diffuser Group -- a single scent diffuser that participants will turn on while they sleep and use for 8 weeks.

Phase < 1
Waitlist Available

University of Alabama at Birmingham

Have you considered Prevpac clinical trials?

We made a collection of clinical trials featuring Prevpac, we think they might fit your search criteria.
Go to Trials
Image of University of North Carolina in Chapel Hill, United States.

MGD020 + MGD014 for HIV

18 - 65
All Sexes
Chapel Hill, NC

This research study aims to find out how safe and well tolerated the experimental study drugs are when given to persons with HIV (PWH) taking antiretroviral therapy (ART). The study treatments are MGD014 and MGD020, which are two antibodies developed specifically for HIV, and Vorinostat, an oral medication to help expose HIV in cells to the antibodies. The study will measure the impact of study treatment on non-active HIV in cells, and how long MGD014 and MGD020 stay in the body after they are given. In this study, participants will be randomly assigned to one of three groups. All participants receive MGD014 and MGD020, given sequentially as infusions through an IV for 4 doses. Participants in one group (group A) receive only MGD014 and MGD020. Participants in another group (group B) will stop taking their ART therapy for up to 8 weeks (a temporary treatment interruption (TTI)) while receiving MGD014 and MGD020. Participants in the third group (group C) receive Vorinostat in addition to MGD014 and MGD020. Total time of participation is about 8 months and involves 13 or 18 visits, depending on group assignment.

Phase 1
Recruiting

University of North Carolina

Cynthia L. Gay, MD

Image of Center on Substance Use and Health in San Francisco, United States.

CHAMPION Intervention for Pre-exposure Prophylaxis Adherence

18 - 40
Male
San Francisco, CA

The goal of this randomized controlled trial is to pilot test new mobile health (mHealth) interventions to improve PrEP adherence among HIV-negative men who have sex with men (MSM) with mild to moderate methamphetamine use disorder (MUD). The CHAMPION intervention combines two mHealth tools-PrEPAPP and CBT4CBT-to address both HIV prevention and MUD treatment needs in this population. The study's specific aims are: * To evaluate the feasibility and acceptability of the CHAMPION intervention based on treatment retention and engagement rates. * To examine the preliminary efficacy the CHAMPION intervention to improve PrEP adherence, as measured by dried blood spot (DBS) tests compared to the waitlist control group.

Waitlist Available
Has No Placebo

Center on Substance Use and Health

Glenn-Milo Santos, PhD, MPH

Have you considered Prevpac clinical trials?

We made a collection of clinical trials featuring Prevpac, we think they might fit your search criteria.
Go to Trials

Have you considered Prevpac clinical trials?

We made a collection of clinical trials featuring Prevpac, we think they might fit your search criteria.
Go to Trials